Results 161 to 170 of about 7,348 (201)
World J Clin CasesSome of the next articles are maybe not open access.
Related searches:
Related searches:
Hospital Pharmacy, 2007
Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and ...
Dennis J. Cada +2 more
openaire +1 more source
Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and ...
Dennis J. Cada +2 more
openaire +1 more source
Mesalamine-Associated Thrombocytopenia
American Journal of Gastroenterology, 1999We describe a case of a 25-yr-old woman with ulcerative colitis who developed marked thrombocytopenia during treatment and upon rechallenge with oral mesalamine. In contrast to its parent drug, sulfasalazine, which has often been reported to cause serious blood disorders, particularly agranulocytosis, mesalamine has rately been implicated as a cause of
R J, Farrell +3 more
openaire +3 more sources
Gastroenterology Nursing, 1992
Asacol (mesalamine) is a delayed release pH-sensitive, polymer-coated, oral preparation of 5-ASA which releases the drug in the terminal ileum and colon for the treatment of mildly to moderately active ulcerative colitis. Treatment modalities using Asacol appear to be an alternative for sulfasalazine-sensitive patients as well as potential first-line ...
openaire +2 more sources
Asacol (mesalamine) is a delayed release pH-sensitive, polymer-coated, oral preparation of 5-ASA which releases the drug in the terminal ileum and colon for the treatment of mildly to moderately active ulcerative colitis. Treatment modalities using Asacol appear to be an alternative for sulfasalazine-sensitive patients as well as potential first-line ...
openaire +2 more sources
Gastroenterology Nursing, 1993
Pentasa (mesalamine) is a newly released oral 5-aminosalicylic acid capsule marketed by Marion Merrel Dow Inc., for the induction of remission and for the treatment of mildly to moderately active ulcerative colitis. Ulcerative colitis is a chronic inflammatory disease and the most common form of inflammatory bowel disease, which is a debilitating and ...
openaire +2 more sources
Pentasa (mesalamine) is a newly released oral 5-aminosalicylic acid capsule marketed by Marion Merrel Dow Inc., for the induction of remission and for the treatment of mildly to moderately active ulcerative colitis. Ulcerative colitis is a chronic inflammatory disease and the most common form of inflammatory bowel disease, which is a debilitating and ...
openaire +2 more sources
Mesalamine-Induced Granulomatous Hepatitis
American Journal of Gastroenterology, 1999A 42-yr-old man with ulcerative colitis was admitted for investigation of prolonged fever associated with cholestatic liver tests. Endoscopic retrograde cholangiopancreatography demonstrated a normal biliary tree, and liver biopsy showed granulomata.
M, Braun +4 more
openaire +2 more sources
Mesalamine in Ulcerative Colitis
DICP, 1991Sulfasalazine has been used for many years in the management of ulcerative colitis. As many as 20 percent of patients treated with it experience intolerable adverse effects usually attributed to its sulfapyridine component. The other active component is 5-aminosalicylic acid (5-ASA); the only 5-ASA enema preparation currently available in the U.S.
J M, Fitzgerald, T D, Marsh
openaire +2 more sources